Telomir Pharmaceuticals announced a $3 million equity investment from its largest shareholder, The Bayshore Trust, purchasing 1 million restricted shares at $3.00 each—an 18% premium to the previous stock price. This investment brings the company's total equity funding from affiliated entities to $4 million, complemented by an additional undrawn $5 million non-dilutive credit line.
The pharmaceutical company is focusing on advancing two key drug candidates: Telomir-1, a first-in-class age-reversal molecule, and Telomir-Ag2, a stabilized Silver(II) compound targeting drug-resistant infections. CEO Erez Aminov emphasized the company's commitment to shareholder-friendly financing, noting the investment includes no warrants or toxic financial structures.
Telomir-1 represents a promising approach to addressing cellular aging by targeting telomeres, the protective end caps of chromosomes. As humans and animals age, telomeres naturally shorten, increasing vulnerability to degenerative diseases. The company plans to submit an Investigational New Drug (IND) application for Telomir-1 by year-end, with an initial focus on rare disease indications to demonstrate early efficacy.
The investment signals growing investor confidence in Telomir's innovative approach to longevity science. By developing a potentially oral-dosed molecule designed to lengthen telomeres, the company aims to not only slow aging processes but potentially enhance overall quality of life for humans and animals.
